Researchers Develop 3D Spheroid Model Showing Dynamic Compression Drives Joint Inflammaging

Researchers have developed a 3D mechanobiological culture platform that models mechanical and age-associated joint inflammaging in human mesenchymal stromal cells, providing a donor-specific screening tool for osteoarthritis therapies.

Researchers at the University of California, Davis, developed an in vitro 3D culture platform that combines gelatin hydrogels, human bone marrow-derived mesenchymal stromal cell (MSC) spheroids, and a compressive bioreactor.

The platform simulates joint-like mechanical environments using dynamic compressive loading of 10 to 20 kPa, preserving cell viability and mechanical stability.

Aged donor-derived MSC spheroids under dynamic loading exhibited metabolic reprogramming toward glycolysis, increased PIEZO1 mechanoreceptor expression, and elevated secretion of pro-inflammatory cytokines IL-6 and IL-8.

The combination of age and mechanical compression amplified inflammatory signaling and promoted pro-inflammatory M1-like macrophage polarization.

Pharmacological validation showed that dexamethasone suppressed inflammatory cytokines and promoted anti-inflammatory M2-like macrophage polarization, whereas the IL-6 inhibitor tocilizumab modulated immune responses without reducing cytokine secretion.

Historically, the dual contribution of age-related cellular changes and mechanical joint stress to osteoarthritis and inflammaging has been challenging to study together in vitro.

By utilizing human donor-derived MSC spheroids, this platform provides a patient-specific screening model to evaluate therapeutic efficacy in age-associated joint diseases.

The findings link mechanical strain directly to metabolic shifting and pro-inflammatory macrophage polarization, suggesting that mechanical loading pathways are crucial targets for disease-modifying osteoarthritis drugs.

This donor-specific screening platform could reduce preclinical development times and reliance on animal models for testing anti-inflammatory and regenerative joint therapies.

Therapeutic strategies aimed at modulating macrophage polarization in osteoarthritic joints receive mechanistic support, as the model demonstrates that mechanical strain in aged environments actively drives M1 macrophage polarization.

Biotechnology firms advancing clinical programs targeted at macrophage reprogramming for joint indications may leverage such model systems to clarify drug mechanisms under physiological loading conditions.

Preclinical validation studies using the 3D platform to test novel mechanotransduction inhibitors, specifically targeting the PIEZO1 pathway in aged joint models.

Academic and clinical development tracking whether therapies that reprogram macrophages to an M2 phenotype can protect joints under active mechanical loading.